Yokohama to Host WCN’26: The World Congress of Nephrology Returns to Japan After 36 Years
26.3.2025 16:59:00 EET | Business Wire | Press release
The World Congress of Nephrology 2026 (WCN’26), the flagship event of the International Society of Nephrology (ISN), is set to take place in Yokohama from March 28 to 31, 2026. The Congress is co-hosted by the Japanese Society of Nephrology (JSN) and the Asian Pacific Society of Nephrology (APSN).
The Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama, in collaboration with the City of Yokohama, supported the bid led by Professor Masaomi Nangaku, President of the Japanese Society of Nephrology. Thanks to PACIFICO Yokohama’s excellent track record in hosting international conferences and the venue’s excellent accessibility, the bid was successfully secured.
Marking a highly anticipated return to Japan after 36 years, the prestigious WCN will bring together leading experts, researchers, and healthcare professionals dedicated to advancing kidney health worldwide. Through dynamic scientific discussions, high-level collaborations, and knowledge exchange, WCN’26 will accelerate advancements in kidney care and strengthen international partnerships.
Comment from Conference Chair, Professor Masaomi Nangaku
“We are thrilled that Yokohama has been chosen as the venue for the World Congress of Nephrology 2026. With its excellent accessibility and convenient hotels, shopping, and conference facilities, Yokohama is the perfect location to promote global collaboration in nephrology research and clinical practices, while further elevating the international presence of the Japanese Society of Nephrology.”
Event Overview
- Event Name: World Congress of Nephrology 2026 (WCN’26)
- Dates: March 28–31, 2026
- Venue: PACIFICO Yokohama
- Expected Attendance: 5,000 participants (including 2,000 from overseas)
- Organizer: International Society of Nephrology (ISN) https://www.theisn.org/
-
Previous and Future Conferences:
2025: New Delhi, India
2024: Buenos Aires, Argentina
2023: Bangkok, Thailand + Virtual
2022: Kuala Lumpur, Malaysia + Virtual
Through their support of international conferences like WCN’26, YCVB and PACIFICO Yokohama are working to boost economic development and foster new business opportunities in the region.
About the Yokohama City Visitors Bureau:
The role of the Yokohama City Visitors Bureau (YCVB) is to employ the wealth of resources existing in the City of Yokohama and Kanagawa Prefecture to promote the region as an ideal destination for both tourists and international conventions. In this way, the YCVB is contributing to the reinvigoration of the City of Yokohama and surrounding areas, and the advancement of its globalization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326550042/en/
Contacts
Yuki Hori
Manager, Business Events Team
Yokohama City Visitors Bureau
Email: mice@ycvb.or.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SuperElastic* Material Unveiled by Angelalign2.11.2026 19:46:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other treatments,“ said Fox Hu, CEO of Angel. MC-SE will be available globally
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 19:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise spanning consumer-facing businesses, healthcare, medtech and life sciences. As Galderma advances its ambition to become the undisputed dermatology powerhouse, spanni
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 16:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key Highlights Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*2. Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorpo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom